Protocol for the Therapy Personalisation Using Multiomic Analyses in Inflammatory Bowel Disease (THAMES‐IBD) Study
Despite an expanding repertoire of advanced therapies for inflammatory bowel disease (IBD), treatment outcomes remain suboptimal, with only 30%–40% of patients achieving sustained remission. Emerging evidence indicates that therapeutic outcomes are shaped by complex interactions between host immune pathways, the...